Proactive Investors - Run By Investors For Investors

Constellation Healthcare Technologies Inc's plan pays off

Constellation Healthcare Technologies’ buy and build strategy certainly appears to be working.
Doctor using a tablet device
The group has more than 9,000 doctors on its books.

Constellation Healthcare Technologies’ (LON:CHT) buy and build strategy certainly appears to be working, judging by the annual results statement.

Revenues rose 40% to US$76.7mln in the 12 months ended last December, giving growth in underlying profits (EBITDA) of US$16.1mln, uo 115%.

Conversion of those profits into cash was good as money it made from operations rose 91% to US$15.5mln.

The layering on of new businesses masked a strong underlying growth rate of 8.8%.

Constellation describes itself as an RCM, or a revenue cycle management company. Essentially, what it does for more than 9,000 doctors on its books is bill and collect monies owed by government, insurers and patients.

It also provides practice management and purchasing services.

Consolidation play 

Obamacare, or the Affordable Care Act to give it its proper name, has created huge upheaval for physicians, complicating the rules on payment while forcing down remuneration.

For the barely profitable small firms carrying out mission-critical billing operations, Obamacare adds a financially onerous level of bureaucracy that is often the final straw.

For Constellation, it has whipped up the perfect storm – or at the very least a great backdrop - against which to consolidate a highly fragmented market.

In December the company unveiled its fourth deal of a fairly short life as a stock market-quoted company when it paid US$30mln for MDRX Medical Billing.

Talking about full-year results, chief executive Paul Parmar said: "Constellation enjoyed a successful year across all metrics.

“We increased our revenue base and more importantly, significantly increased our profitability for the year.

“Our acquisition and integration strategy is proven and we are quickly becoming one of the largest healthcare and technology services businesses in the US.”

finnCap’s punchy price target

The broker reckons the stock is worth 310p more than double the closing share price.

It points out the business is trading on a forward multiple of less than 10 times earnings 8%-plus free cash flow.


Register here to be notified of future CHT Company articles
View full CHT profile View Profile

Constellation Healthcare Technologies, Inc. Timeline

Related Articles

pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use